More than two decades have elapsed since the publication of the first genome sequence of
Mycobacterium tuberculosis (Mtb) which, shortly thereafter, enabled methods to determine …

Abstract Decaprenyl-phosphoryl-ribose 2′-epimerase (DprE1) inhibitors are an innovative
and futuristic orally active group of antituberculosis agents. A few DprE1 inhibitors are in the …

Phenotypic screens for bactericidal compounds are starting to yield promising hits against
tuberculosis. In this regard, whole-genome sequencing of spontaneous resistant mutants …

Tuberculosis (TB) is an infection caused by Mycobacterium tuberculosis, responsible for 1.5
million documented deaths in 2016. The increase in reported cases of M. tuberculosis …

The emergence of drug-resistant mycobacteria, including Mycobacterium tuberculosis (Mtb)
and non-tuberculous mycobacteria (NTM), poses an increasing global threat that urgently …

Tuberculosis and bacterial infections are major challenges because of elevated infection
rates and drug resistance. New chemical agents need to be developed to address them …

Despite the discovery of the tubercle bacillus more than 130 years ago, its physiology and
the mechanisms of virulence are still not fully understood. A comprehensive analysis of the …

Recent studies have reported the β-ketoacyl-acyl carrier protein KasA as a druggable target
for Mycobacterium tuberculosis. This review summarizes the current status of major classes …

In the current study, two sets of compounds:(E)-1-(2-(4-substitutedphenyl)-2-oxoethyl)-4-
((hydroxyimino) methyl) pyridinium derivatives (3a-3e); and (E)-3-(substitutedbenzoyl)-7 …

ABSTRACT We report GSK3011724A (DG167) as a binary inhibitor of β-ketoacyl-ACP
synthase (KasA) in Mycobacterium tuberculosis. Genetic and biochemical studies …